| Item Type | Name |
|
Concept
|
Carcinoma
|
|
Concept
|
Carcinoma in Situ
|
|
Concept
|
Carcinoma, Squamous Cell
|
|
Concept
|
Carcinoma, Adenosquamous
|
|
Concept
|
Carcinoma, Endometrioid
|
|
Academic Article
|
Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era.
|
|
Academic Article
|
Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.
|
|
Academic Article
|
Nodal metastasis risk in endometrioid endometrial cancer.
|
|
Academic Article
|
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.
|
|
Academic Article
|
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
|
|
Academic Article
|
A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study.
|
|
Academic Article
|
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).
|
|
Academic Article
|
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Tubal ligation frequency in Oklahoma women with cervical cancer.
|
|
Academic Article
|
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial.
|
|
Academic Article
|
Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
|
|
Academic Article
|
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
|
|
Academic Article
|
Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer.
|
|
Academic Article
|
Intraperitoneal chemotherapy for ovarian cancer.
|
|
Academic Article
|
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
|
|
Academic Article
|
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.
|
|
Academic Article
|
Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study.
|
|
Academic Article
|
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
|
|
Academic Article
|
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
|
|
Academic Article
|
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.
|
|
Academic Article
|
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
|
|
Academic Article
|
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
|
|
Academic Article
|
A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study.
|
|
Academic Article
|
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?
|
|
Academic Article
|
Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients.
|
|
Academic Article
|
The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study.
|
|
Academic Article
|
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
|
|
Academic Article
|
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
|
|
Academic Article
|
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
|
|
Academic Article
|
Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging.
|
|
Academic Article
|
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
|
|
Academic Article
|
Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group.
|
|
Academic Article
|
Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS).
|
|
Academic Article
|
Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation.
|
|
Academic Article
|
Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes.
|
|
Academic Article
|
Sexual function of patients with endometrial cancer enrolled in the Gynecologic Oncology Group LAP2 Study.
|
|
Academic Article
|
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.
|
|
Academic Article
|
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
|
|
Academic Article
|
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.
|
|
Academic Article
|
Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2.
|
|
Academic Article
|
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
|
|
Academic Article
|
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
|
|
Academic Article
|
Reply to F. Tomao et al and E.A. De Jaeghere et al.
|
|
Academic Article
|
Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival.
|
|
Academic Article
|
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
|
|
Academic Article
|
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
|
|
Academic Article
|
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
|
|
Academic Article
|
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
|
|
Academic Article
|
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
|